New Device Aims to Measure Brain's Waste-Clearing System During Sleep
Applied Cognition tests a wearable device that tracks glymphatic function overnight, comparing it to MRI, EEG, and blood biomarkers.
Summary
The glymphatic system is the brain's nightly cleanup crew, flushing out toxic proteins linked to Alzheimer's and cognitive decline. Measuring how well it works has traditionally required expensive MRI scans in clinical settings. Applied Cognition ran a completed crossover randomized study in healthy older adults to validate a non-invasive investigational device that monitors glymphatic function during sleep and wakefulness. Participants wore the device during overnight sleep and morning wake, and again during overnight wake and morning sleep, allowing direct comparison with MRI neuroimaging, EEG readings, and blood biomarkers alongside cognitive tests. If validated, such a device could make routine glymphatic monitoring practical and accessible, opening the door to early detection of neurodegeneration risk and real-time tracking of interventions like sleep optimization, exercise, or pharmacological therapies targeting brain health.
Detailed Summary
The brain's glymphatic system performs critical nightly maintenance, clearing amyloid-beta, tau, and other metabolic waste products that accumulate during waking hours. Dysfunction in this system has been strongly linked to Alzheimer's disease, Parkinson's disease, and accelerated cognitive aging. Until now, assessing glymphatic activity reliably has required specialized MRI protocols — expensive, time-consuming, and impractical for routine clinical or consumer use.
Applied Cognition designed this completed crossover randomized trial to validate an investigational medical device against established gold-standard measurements of glymphatic function. Healthy older volunteers were enrolled and subjected to two sleep-wake schedule conditions: device measurements during overnight sleep paired with morning wakefulness, and the reverse — overnight wakefulness paired with morning sleep. This crossover design allows each participant to serve as their own control, strengthening the comparison.
Validation benchmarks included MRI-based neuroimaging for direct glymphatic activity measurement, EEG recordings to capture sleep architecture and neural oscillations, blood biomarkers reflecting neuroinflammation and waste clearance, and standardized cognitive test batteries. The multi-modal approach gives a comprehensive picture of whether the device accurately reflects underlying brain biology.
The implications are significant. A validated, wearable or home-based glymphatic monitoring device would transform both clinical practice and personal health optimization. Clinicians could track patients at risk for neurodegeneration longitudinally without repeated MRI referrals. Individuals optimizing sleep quality, timing, or supplementation could receive objective feedback on whether their interventions are actually improving brain clearance function.
Important caveats apply. The trial enrolled only healthy older adults, so results may not generalize to those with existing neurological conditions or sleep disorders. Crucially, this summary is based on the abstract alone — device performance metrics, correlation coefficients with MRI, and full statistical outcomes have not been publicly reported. The trial sponsor is the device manufacturer, introducing potential bias.
Key Findings
- Investigational device aims to measure glymphatic function non-invasively during sleep without MRI.
- Crossover design lets each participant serve as their own control, improving validation rigor.
- Device compared against MRI neuroimaging, EEG, blood biomarkers, and cognitive tests simultaneously.
- Completed status suggests data collection is finished; published results are not yet available.
- If validated, could enable routine at-home monitoring of brain waste-clearance efficiency.
Methodology
This is a completed crossover randomized trial enrolling healthy older adults. Participants underwent device measurements under two conditions — overnight sleep with morning wake, and overnight wake with morning sleep — with glymphatic function validated against MRI neuroimaging, EEG, blood biomarkers, and cognitive assessments.
Study Limitations
This summary is based on the abstract only; full methodology, results, and statistical outcomes have not been publicly disclosed. The study enrolled only healthy older adults, limiting generalizability to populations with sleep disorders or neurodegenerative conditions. Sponsor-led validation studies carry inherent conflict-of-interest risk that independent replication would need to address.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.